Laboratory for Radiopharmacy, Ghent University, Ghent, Belgium.
Laboratory for Radiopharmacy, Ghent University, Ghent, Belgium.
Nucl Med Biol. 2020 Mar-Apr;82-83:9-16. doi: 10.1016/j.nucmedbio.2019.12.002. Epub 2019 Dec 9.
Considering the need for rapid change of treatment in recurrent glioblastoma (GB), it is of utmost importance to characterize PET radiopharmaceuticals that allow early discrimination of tumor from therapy-related effects. In this study, we examined the value of 2-[F]FELP as a LAT1 tumor-specific PET tracer in comparison with [F]FDG and [F]FET in a combined orthotopic rat radiation necrosis and glioblastoma model. A second experiment compared 2-[F]FELP to [F]FDG in a mouse glioblastoma - inflammation model.
Using the small animal radiation research platform (SARRP), radiation necrosis (RN) was induced in the left frontal lobe of the rat brain. When radiation-induced changes were visible on MRI, F98 rat glioblastoma cells were stereotactically inoculated in the contralateral right frontal lobe. When tumor growth was confirmed on MRI, 2-[F]FELP, [F]FET and [F]FDG PET scans were acquired on three consecutive days. In an inflammation experiment, mice were inoculated in the left thigh with U87 human glioblastoma cells. After heterotopic tumor growth was confirmed macroscopically, inflammation was induced by injection of turpentine subcutaneously in the right thigh. Subsequently, 2-[F]FELP and [F]FDG scans were acquired on two consecutive days.
The in vivo PET images demonstrated that 2-[F]FELP could differentiate glioblastoma and radiation necrosis using SUV (p = 0.0016) and LNR (p = 0.009), while [F]FET was only able to differentiate both lesions by means of the SUV. (p = 0.047) Delayed [F]FDG PET (4 h postinjection) was also able to distinguish glioblastoma from radiation necrosis, but smaller lesion-to-normal brain ratios were observed (SUV: p = 0.009; LNR: p = 0.028). In the inflammation study, 2-[F]FELP showed no significant uptake in the inflammation lesion when compared to the control group (SUVmean: p = 0.149; LNRmean: p = 0.083). In contrast, both conventional and delayed [F]FDG displayed significant uptake in the turpentine-invoked lesion (SUVmean: p = 0.021; LNRmean: p = 0.021).
This study suggests that the 2-[F]FELP PET is able to differentiate glioblastoma from radiation necrosis and that the 2-[F]FELP uptake is less likely to be contaminated by the presence of inflammation than the [F]FDG signal.
These results are clinically relevant for the differential diagnosis between tumor and radiation necrosis because radiation necrosis always contains a certain amount of inflammatory cells. Hence, 2-[F]FELP is preferred to discriminate tumor from radiation necrosis.
考虑到复发性胶质母细胞瘤(GB)治疗需要快速改变,因此,表征允许早期区分肿瘤与治疗相关效应的 PET 放射性药物至关重要。在这项研究中,我们研究了 2-[F]FELP 作为 LAT1 肿瘤特异性 PET 示踪剂的价值,与 [F]FDG 和 [F]FET 在联合原位大鼠放射性坏死和胶质母细胞瘤模型中的比较。第二个实验比较了 2-[F]FELP 与 [F]FDG 在小鼠胶质母细胞瘤-炎症模型中的比较。
使用小动物放射研究平台(SARRP),在大鼠左额叶诱导放射性坏死(RN)。当 MRI 上出现放射性变化时,立体定向接种 F98 大鼠胶质母细胞瘤细胞至对侧右额叶。当 MRI 上确认肿瘤生长时,连续三天进行 2-[F]FELP、[F]FET 和 [F]FDG PET 扫描。在炎症实验中,将 U87 人胶质母细胞瘤细胞接种于小鼠左大腿。宏观确认异位肿瘤生长后,在右大腿皮下注射松节油诱导炎症。随后,连续两天进行 2-[F]FELP 和 [F]FDG 扫描。
体内 PET 图像表明,2-[F]FELP 可通过 SUV(p=0.0016)和 LNR(p=0.009)区分胶质母细胞瘤和放射性坏死,而 [F]FET 仅通过 SUV 区分两种病变(p=0.047)。延迟的 [F]FDG PET(注射后 4 小时)也能够区分胶质母细胞瘤和放射性坏死,但观察到较小的病变与正常脑比值(SUV:p=0.009;LNR:p=0.028)。在炎症研究中,与对照组相比,2-[F]FELP 在炎症病变中没有明显摄取(SUVmean:p=0.149;LNRmean:p=0.083)。相比之下,常规和延迟的 [F]FDG 在松节油诱导的病变中均有明显摄取(SUVmean:p=0.021;LNRmean:p=0.021)。
本研究表明,2-[F]FELP PET 能够区分胶质母细胞瘤和放射性坏死,并且 2-[F]FELP 摄取不太可能受到炎症信号的污染,而比 [F]FDG 信号更不受污染。
这些结果与肿瘤与放射性坏死的鉴别诊断具有临床相关性,因为放射性坏死总是包含一定数量的炎症细胞。因此,2-[F]FELP 优先用于区分肿瘤与放射性坏死。